

## SWOG ASCO 2022 ABSTRACTS

### SWOG-LED:

LUNGMAP Vaidya R, Unger J, Qian L, Minichiello K, Herbst RS, Gandara D, Neal J, Leal T, Patel J, Dragnev K, Waqar S, Edelman M, Sigal E, Adam S, Malik S, Blanke CD, LeBlanc M, Kelly K, Redman M. Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session, 2022. <https://meetings.asco.org/abstracts-presentations/206721>

MULTIPLE Unger J, Xiao H, Vaidya R, Hershman D. The Medicaid Expansion of the Affordable Care Act and Participation of Patients with Medicaid in SWOG Cancer Clinical Trials. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral, 2022. <https://meetings.asco.org/abstracts-presentations/206536>

NONE Dizon D, Szczepanek C, Petrylak D, Sparks D, Tangen C, Lara P, Thompson IM, Blanke CD. National impact of the COVID-19 pandemic on clinical trial staff attrition: Results of the SWOG Cancer Research Network survey of Oncology Research Professionals. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session, 2022. <https://meetings.asco.org/abstracts-presentations/210284>

NONE Moerdler S, Barry M, Henry E, Lucas T, Marshall A, Dizon D. Impact of Social Media on the Wellness of Pediatric and Adult Oncologists: A SWOG and COG survey. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster discussion, 2022. <https://meetings.asco.org/abstracts-presentations/209277>

S0221 Chen C-S, Zirpoli G, McCann S, Barlow W, Budd GT, Puztai L, Hortobagyi G, Godwin A, Thompson A, Ambrosone C, Stringer K, Hertz D. Vitamin D Insufficiency as a Peripheral Neuropathy Risk Factor in White and Black Patients in SWOG 0221. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster discussion, 2022. <https://meetings.asco.org/abstracts-presentations/209887>

S0800 Blenman K, Fanucci K, Bai Y, Pelekanou V, Nahleh Z, Shafi S, Burela S, Barlow W, Sharma P, Thompson A, Godwin A, Rimm D, Hortobagyi G, Puztai L. Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating lymphocyte measurements. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session, 2022. <https://meetings.asco.org/abstracts-presentations/209317>

S0931 Ryan CW, Tangen C, Heath E, Stein M, Meng M, Alva A, Pal S, Puzanov I, Clark J, Choueiri T, Agarwal N, Uzzo R, Haas N, Synold T, Plets M, Vaishampayan U, Shuch B, Vogelzang N, Thompson I, Lara P. EVEREST: EVERolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study (SWOG S0931, NCT01120249). ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral, 2022. <https://meetings.asco.org/abstracts-presentations/207883>

- S1211 Usmani S, Hoering A, Ailawadhi S, Sexton R, Lipe B, Valent J, Rosenzweig M, Zonder J, Dhodapkar M, Callandar N, Zimmerman T, Voorhees P, Durie B, Rajkumar V, Richardson P, Orlowski R. Follow-Up Analysis of the Randomized Phase II Trial of Bortezomib, Lenalidomide, Dexamethasone with/without Elotuzumab for Newly Diagnosed, High Risk Multiple Myeloma (SWOG-1211). ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session, 2022. <https://meetings.asco.org/abstracts-presentations/207925>
- S1216 Lara P, Mayerson E, Gertz E, Tangen C, Goldkorn A, Van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn D, Vogelzang N, Agarwal N. Bone biomarkers and subsequent survival in men with hormone sensitive prostate cancer: results from SWOG S1216, a phase III trial of ADT with or without orteronel. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session, 2022. <https://meetings.asco.org/abstracts-presentations/212130>
- S1314 Iyer G, Tangen C, Sarfaty M, Regazzi A, Thompson IM, McConkey D, Flaig T, Rosenberg J. Association of DNA damage response (DDR) gene alterations (alts) and response to neoadjuvant cisplatin-based chemotherapy (chemo) in muscle-invasive bladder cancer (MIBC) patients (pts) enrolled onto SWOG S1314. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session, 2022. <https://meetings.asco.org/abstracts-presentations/209535>
- S1314 Lu Y-T, Plets M, Morrison G, Cunha A, Cen S, Rhie S, Siegmund K, Daneshmand S, Quinn D, Lerner S, Petrylak D, McConkey D, Flaig T, Thompson I, Goldkorn A. Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle invasive bladder cancer in SWOG S1314. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral, 2022. <https://meetings.asco.org/abstracts-presentations/209215>
- S1314 Plimack E, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, Ross E, Grundy E, Choi W, Dinney C, Lee I-L, Lucia MS, Flaig T, McConkey D. S1314 Correlative analysis of ATM, RB1, ERCC2 and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): implications for bladder preservation. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session, 2022. <https://meetings.asco.org/abstracts-presentations/209575>
- S1400I Gonzalez-Kozlova E, Huang H-H, Redman M, Herbst R, Gettinger S, Bazhenova L, Xie H, Patel M, Nie K, Harris J, Argueta C, Kelly K, Cerami E, Biswas R, Van Nostrand S, Moravic R, Del Valle D, Kim-Schulze S, Gnjjatic S. Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab + ipilimumab. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session, 2022. <https://meetings.asco.org/abstracts-presentations/209307>
- S1400I Parra E, Duose D, Zhang J, Redman M, Lazcano R, Piubelli M, Laberiana Fernandez C, Zhang B, Cerami E, Lindsay J, Yu J, Biswas R, Van Nostrand S, Moravec R, Kannan K, Luthra R, Al-Atrash G, Kelly K, Herbst R, Wistuba I, Gettinger S, Bazhenova L, Lee J, Zhang J, Zhang J, Haymaker C. Multi-omics profiling reveals molecular and immune features associated with benefit from immunotherapy for

Previously Treated Stage IV or recurrent Squamous Cell Lung Cancer patients from the Phase III SWOG LungMAP S1400I trial. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session, 2022. <https://meetings.asco.org/abstracts-presentations/212896>

S1415CD Hershman DL, Bansal A, Sullivan S, Lyman G, Barlow W, Arnold K, Watabayashi K, Bell-Brown A, Le-Lindqwister N, Dul C, Brown-Glaberman U, Behrens R, Vogel V, Alluri N, Ramsey SD. A Pragmatic Cluster-Randomized Trial of a Standing Physician Order Entry Intervention for Colony Stimulating Factor use among Patients at Intermediate Risk for Febrile Neutropenia (SWOG S1415CD). ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster discussion, 2022. <https://meetings.asco.org/abstracts-presentations/209533>

S1415CD Ramsey S, Bansal A, Sullivan S, Lyman G, Barlow W, Arnold K, Watabayashi K, Bell-Brown A, Le-Lindqwister N, Dul C, Brown-Glaberman U, Behrens R, Vogel V, Alluri N, Hershman D. A pragmatic cluster-randomized trial of a computerized clinical decision support system to improve colony stimulating factor prescribing for cancer patients receiving myelosuppressive chemotherapy (SWOG S1415CD). ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session, 2022. <https://meetings.asco.org/abstracts-presentations/212455>

S1512 Kendra K, Moon J, Eroglu Z, Hu-Lieskovan S, Carson W, Wada D, Plaza J, In G, Ikeguchi A, Hyingstrom J, Brohl A, Chmielowski B, Khushalani N, Markowitz J, Monroe M, Grossmann K, Sondak V, Sharon E, Wu M, Ribas A. Neoadjuvant PD-1 Blockade in Patients with Resectable Desmoplastic Melanoma (SWOG 1512). ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral presentation, 2022. <https://meetings.asco.org/abstracts-presentations/206806>

S1714 Trivedi M, Unger J, Hershman D, Darke A, Hertz D, Brannagan T, Smith SJ, Irvin W, Hathaway A, Vander Woude A, Gudena V, Henry NL, Fisch M. Differences in clinician and patient assessment of baseline neuropathy in patients receiving taxane-based chemotherapy enrolled to SWOG S1714 (NCT# 03939481). ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster discussion, 2022. <https://meetings.asco.org/abstracts-presentations/209883>

S1800A Reckamp K, Redman M, Dragnev K, Villaruz L, Faller B, Al Baghdadi T, Hines S, Qian L, Minichiello K, Gandara D, Kelly K, Herbst R. Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy: Lung-MAP non-matched sub-studyS1800A. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral, 2022. <https://meetings.asco.org/abstracts-presentations/208275>

S1900C Skoulidis F, Redman M, Suga J, Al Baghdadi T, Villano J, Goldberg S, Villaruz L, Minichiello K, Gandara D, Herbst R, Kelly K. A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic Stk11 Genomic Alterations (SWOG S1900C, LUNG-MAP SUB-STUDY, NCT#04173507). ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session, 2022. <https://meetings.asco.org/abstracts-presentations/212875>

S1937 Sadeghi S, Plets M, Lara P, Tangen C, Bangs R, Lerner S, Flaig T, Petrylak D, Thompson IM. A Phase III Randomized Trial of Eribulin (E) with or without Gemcitabine vs Standard of Care (SOC) for Metastatic Urothelial Carcinoma (UC) Refractory to or Ineligible for PD/PDL1 Antibody (Ab): SWOG S1937 (ClinicalTrials.gov NCT04579224). ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), TIPS, poster session, 2022. <https://meetings.asco.org/abstracts-presentations/213077>

S2012 Zhen D, Mayerson E, Chiorean EG, Burgess E, Swisher E, Byers L, Gay C, Wistuba I, Mahdi H, Das S, Starr J, Othus M, Ruzrock R. SWOG 2012: Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (Nsc#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC). ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session, 2022. <https://meetings.asco.org/abstracts-presentations/213198>

#### **OTHER GROUP -LED AND CO-LED:**

MULTIPLE\* Halabi S, Roy A, Rydzewska L, Godolphin P, Parmar M, Hussain M, Tangen C, Thompson I, Xie W, Carducci M, Smith M, Gravis G, Dearnaley D, Verhagen P, Goto T, James N, Buyse M, Tierney J, Sweeney C. Assessing Intermediate Clinical Endpoints (ICE) as Potential Surrogates for Overall Survival (OS) in men with Metastatic Hormone Sensitive Prostate Cancer(mHSPC). ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), 2022. [\*S9346 data included with multiple other] oral, 2022. <https://meetings.asco.org/abstracts-presentations/210861>

C80405 [Co-Led] Arai H, Yang Y, Millstein J, Denda Y, Ou F-S, Innocenti F, Takeda H, Doi A, Horie Y, Umemoto K, Izawa N, Wang J, Battaglin F, Kawanishi N, Jayachandran P, Soni S, Zhang W, Venook A, Sunakawa Y, Lenz H-J. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC) . ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), 2022. ARAI Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance) poster session, 2022. <https://meetings.asco.org/abstracts-presentations/208468>

C80405 [Co-led] Zhang W, Battaglin F, Yang Y, Ou F-S, Innocenti F, Arai H, Soni S, Jayachandran P, Bertagnolli M, Hochster H, Niedzwiecki D, Goldberg R, Mayer R, Blanke CD, Venook A, Kabbarah O, Millstein J, Lenz H-J. Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), 2022. poster session. <https://meetings.asco.org/abstracts-presentations/208442>

C80405 Kohn C, Ou F-S, Ma C, Larson N, Zemla T, Yuan C, Niedzwiecki D, Hollis B, Nixon A, Lenz H-J, Blanke CD, Goldberg R, Mayer R, Venook A, O'Reilly E, Meyerhardt J, Ng K. Gene Expression of Vitamin D (VitD) Pathway Markers and Survival in Patients (Pts) with Metastatic Colorectal Cancer (mCRC): Findings from CALGB/SWOG 80405 (Alliance). ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), 2022. poster session. <https://meetings.asco.org/abstracts-presentations/208514>

- A051902 Mehta-Shah N, Bartlett N, Barta S, Amengual J, Horwitz S, Kahl B, Friedberg J, Dockter T, Geyer S, Leonard J. A059102: A Randomized Phase II US Intergroup Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), 2022, poster session. <https://meetings.asco.org/abstracts-presentations/213330>
- E1Q11 Patel A, Lee J-W, Zaren H, Radeke E, Lerner R, Fukui J, Makower D, Tamkus D, Rosland K, Adler W, Throckmorton A, Ghamande S, Cella D, Fisch MJ, Wagner L. Cluster-randomized trial to evaluate the implementation of reproductive health care in cancer care delivery in community oncology practices: Results from ECOG-ACRIN E1Q11. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster discussion session 2022. <https://meetings.asco.org/abstracts-presentations/209559>
- EA2142 Eads J, Catalano P, Fisher G, Rubin D, Lagaru A, Klimstra D, Konda B, Kwong M, Chan J, De Jesus-Acosta A, Halfdanarson T, Shaib W, Soares H, Hong S, Wong T, O'Dwyer P. Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster discussion session 2022. <https://meetings.asco.org/abstracts-presentations/209225>
- EA2186 Dotan E, Catalano P, Lenchik L, Boutin R, Yao X, Gatsonis C, Zhen D, Li D, Wagner L, Simon M, Wong T, O'Dwyer P. EA-2186: A randomized phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in older patients with treatment naive metastatic pancreatic cancer (GIANT): Trials in Progress. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), I, poster session 2022. <https://meetings.asco.org/abstracts-presentations/213069>
- EA2201 Ciombor K, Hong S, Eng C, Yao X, Thet Cho M, You YN, Das P, Chakravarthy A, O'Dwyer P. EA2201: An ECOG-ACRIN phase II study of neoadjuvant nivolumab plus ipilimumab and short course radiation in MSI-H/dMMR rectal tumors. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session 2022. <https://meetings.asco.org/abstracts-presentations/213290>
- EA3202 Bhatia A, Flamand Y, Johnson J, Ishizuka J, Duan F, Tang M, Karivedu V, Subramaniam R, Burtneess B. A Phase II/III Trial of Chemotherapy + Cetuximab vs. Chemotherapy + Bevacizumab vs. Atezolizumab + Bevacizumab Following Progression on ImmuneCheckpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers: ECOG-ACRIN EA3202. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session 2022. <https://meetings.asco.org/abstracts-presentations/213132>
- EA6134 Jensen R, Zheng Y, Atkins M, Chmielowski B, Tarhini A, Truong T-G, Divar D, O'Rourke M, Curti B, Brell J, Kendra K, Ikeguchi A, Lee S, Potosky A, Wolchok J. Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy vs targeted therapy in patients (pts) with BRAF mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134). ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session 2022. <https://meetings.asco.org/abstracts-presentations/210452>

- EA6192 Gibney G, Lee S, Atkins M, Wong T, Guerriero J, Marron T, Cohen G, Truong T-G, Carvajal R, Snyder B, Farwell M, Kirkwood J, Wolchok J. A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop): ECOG-ACRIN EA6192. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session 2022. <https://meetings.asco.org/abstracts-presentations/213286>
- EA8183 Morgans A, Chen Y, Ferrari A, Tran P, Schaeffer E, Shevrin D, Szmulewitz R, Boike T, Dorff T, Liu G, Wagner L, Carducci M. A Phase III Double Blinded Study of Early Intervention After RADICAL ProstaTEctomy With Androgen Deprivation Therapy With Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE). ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session 2022. <https://meetings.asco.org/abstracts-presentations/213495>
- EA8185 Joshi M, Kim S, Solanki A, Miyamoto D, Degraff D, Zou J, Meeks J, Mitin T, Collins S, Trabulsi E, Hahn N, Efstathiou J, Carducci M. EA8185: Phase 2 Study of Bladder-Sparing Chemoradiation (chemoRT) with Durvalumab in Clinical Stage III, Node Positive Urothelial Carcinoma (INSPIRE), an ECOG-ACRIN/NRG Collaboration. ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), 2022. TIPS, poster session, 2022. <https://meetings.asco.org/abstracts-presentations/213335>